Capstan Medical is developing a first-of-its-kind catheter-based robotic delivery platform and a suite of next-generation heart valve implants to expand percutaneous treatment options. The company’s solution targets mitral and tricuspid valve disease and aims to overcome limitations of open-heart surgery and existing catheter-based options. Capstan has grown to over 75 employees across engineering, operations, clinical, and regulatory. Since its founding in 2020, the team has focused on combining novel implants, advanced catheter technology, and robotics to treat a broader set of patients. With new funding, the company plans to continue expanded clinical and development work and advance toward upcoming pivotal trials. Capstan Medical is developing a suite of next-generation heart valve implants and a first-of-its-kind catheter-based robotic delivery platform for minimally invasive treatment of heart valve disease. The company’s catheter-based approach enables procedures through a small groin incision without stopping the heart or opening the chest, shortening recovery from months to weeks. Capstan plans to use the new funding to expand engineering, clinical development, and operations teams and to progress the technology toward first human use. The company is led by CEO Maggie Nixon and CTO Dan Wallace. Capstan was founded in 2020 and is based in Santa Cruz, CA. The firm emphasizes treating even very sick patients with less invasive catheter-based techniques.

Total raised

$141M

Funding rounds

2

Latest round

Series C

Latest activity

Dec 2024